NLRP3 and metabolic dysfunction-associated steatohepatitis: Exenatide effectively reduces NLRP3, caspase-1, and IL-1β expression in HepG2 cells induced by oleic acid/LPS and in mice with MCD diet-induced liver injury, thus suppressing pyroptosis and alleviating MASH symptoms (Liu et al., 2021).